Titre : Tumeurs des voies biliaires

Tumeurs des voies biliaires : Questions médicales fréquentes

Termes MeSH sélectionnés :

Multicenter Studies as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Tumeurs des voies biliaires : Questions médicales les plus fréquentes", "headline": "Tumeurs des voies biliaires : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Tumeurs des voies biliaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-20", "dateModified": "2025-04-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Tumeurs des voies biliaires" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tumeurs de l'appareil digestif", "url": "https://questionsmedicales.fr/mesh/D004067", "about": { "@type": "MedicalCondition", "name": "Tumeurs de l'appareil digestif", "code": { "@type": "MedicalCode", "code": "D004067", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C06.301" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Tumeurs des canaux biliaires", "alternateName": "Bile Duct Neoplasms", "url": "https://questionsmedicales.fr/mesh/D001650", "about": { "@type": "MedicalCondition", "name": "Tumeurs des canaux biliaires", "code": { "@type": "MedicalCode", "code": "D001650", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C06.301.120.250" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Tumeurs du cholédoque", "alternateName": "Common Bile Duct Neoplasms", "url": "https://questionsmedicales.fr/mesh/D003138", "about": { "@type": "MedicalCondition", "name": "Tumeurs du cholédoque", "code": { "@type": "MedicalCode", "code": "D003138", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C06.301.120.250.250" } } } ] }, { "@type": "MedicalWebPage", "name": "Tumeurs de la vésicule biliaire", "alternateName": "Gallbladder Neoplasms", "url": "https://questionsmedicales.fr/mesh/D005706", "about": { "@type": "MedicalCondition", "name": "Tumeurs de la vésicule biliaire", "code": { "@type": "MedicalCode", "code": "D005706", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C06.301.120.401" } } } ], "about": { "@type": "MedicalCondition", "name": "Tumeurs des voies biliaires", "alternateName": "Biliary Tract Neoplasms", "code": { "@type": "MedicalCode", "code": "D001661", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yasuni Nakanuma", "url": "https://questionsmedicales.fr/author/Yasuni%20Nakanuma", "affiliation": { "@type": "Organization", "name": "Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan; Department of Diagnostic Pathology, Fukui Prefecture Saiseikai Hospital, Japan. Electronic address: nakanumayasu@gmail.com." } }, { "@type": "Person", "name": "Takashi Sugino", "url": "https://questionsmedicales.fr/author/Takashi%20Sugino", "affiliation": { "@type": "Organization", "name": "Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan." } }, { "@type": "Person", "name": "Yasunori Sato", "url": "https://questionsmedicales.fr/author/Yasunori%20Sato", "affiliation": { "@type": "Organization", "name": "Department of Human Pathology, Kanazawa University School of Medicine, Kanazawa, Japan." } }, { "@type": "Person", "name": "Hans-Olov Adami", "url": "https://questionsmedicales.fr/author/Hans-Olov%20Adami", "affiliation": { "@type": "Organization", "name": "Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden." } }, { "@type": "Person", "name": "Gary E Fraser", "url": "https://questionsmedicales.fr/author/Gary%20E%20Fraser", "affiliation": { "@type": "Organization", "name": "School of Public Health, Loma Linda University, Loma Linda, California." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A Simplified Clinical Prediction Rule for Prognosticating Dependent Daily Living in Patients with Thoracic Spinal Cord Injury: A Multicenter Nationwide Japan Registry Study.", "datePublished": "2023-03-03", "url": "https://questionsmedicales.fr/article/36871549", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000529780" } }, { "@type": "ScholarlyArticle", "name": "A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.", "datePublished": "2023-02-28", "url": "https://questionsmedicales.fr/article/36880014", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2147/CPAA.S397826" } }, { "@type": "ScholarlyArticle", "name": "Intraoperative complication of radical cystectomy for muscle-invasive bladder cancer: does the surgical approach matter? A retrospective multicenter study using the EAUiaiC classification.", "datePublished": "2023-02-27", "url": "https://questionsmedicales.fr/article/36847814", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00345-023-04340-z" } }, { "@type": "ScholarlyArticle", "name": "Artificial intelligence-based computer-aided diagnosis system supports diagnosis of lymph node metastasis in esophageal squamous cell carcinoma: A multicenter study.", "datePublished": "2023-02-25", "url": "https://questionsmedicales.fr/article/36923854", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.heliyon.2023.e14030" } }, { "@type": "ScholarlyArticle", "name": "Estimation of the physiologic ability and surgical stress scoring system as a useful predictor of postoperative recurrence in patients with stage II colorectal cancer: a multicenter study.", "datePublished": "2023-02-15", "url": "https://questionsmedicales.fr/article/36790474", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00595-023-02656-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies de l'appareil digestif", "item": "https://questionsmedicales.fr/mesh/D004066" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs de l'appareil digestif", "item": "https://questionsmedicales.fr/mesh/D004067" }, { "@type": "ListItem", "position": 4, "name": "Tumeurs des voies biliaires", "item": "https://questionsmedicales.fr/mesh/D001661" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Tumeurs des voies biliaires - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Tumeurs des voies biliaires", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Tumeurs des voies biliaires", "description": "Comment diagnostique-t-on une tumeur des voies biliaires ?\nQuels tests sanguins sont utiles pour le diagnostic ?\nQuelle est l'importance de l'IRM dans le diagnostic ?\nPeut-on utiliser la cholangiographie pour le diagnostic ?\nQuels symptômes peuvent alerter sur une tumeur ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=991#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Tumeurs des voies biliaires", "description": "Quels sont les symptômes courants des tumeurs biliaires ?\nLa jaunisse est-elle un symptôme fréquent ?\nPeut-on avoir des démangeaisons avec une tumeur biliaire ?\nLes nausées sont-elles un symptôme associé ?\nComment la douleur abdominale se manifeste-t-elle ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=991#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Tumeurs des voies biliaires", "description": "Peut-on prévenir les tumeurs des voies biliaires ?\nQuels facteurs de risque sont évitables ?\nL'alimentation joue-t-elle un rôle ?\nLes infections chroniques augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=991#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Tumeurs des voies biliaires", "description": "Quels sont les traitements possibles pour ces tumeurs ?\nLa chirurgie est-elle toujours possible ?\nQuand la chimiothérapie est-elle recommandée ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements ciblés disponibles ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=991#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Tumeurs des voies biliaires", "description": "Quelles complications peuvent survenir ?\nL'obstruction biliaire est-elle grave ?\nLes infections sont-elles fréquentes ?\nQuelles sont les conséquences des métastases ?\nPeut-on prévenir les complications ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=991#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Tumeurs des voies biliaires", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de tumeurs biliaires ?\nLes maladies hépatiques augmentent-elles le risque ?\nL'exposition à l'arsenic est-elle un risque ?\nLes antécédents familiaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Multicenter+Studies+as+Topic&page=991#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on une tumeur des voies biliaires ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par imagerie (échographie, IRM) et biopsie." } }, { "@type": "Question", "name": "Quels tests sanguins sont utiles pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent les marqueurs tumoraux comme l'ACE et les tests de fonction hépatique." } }, { "@type": "Question", "name": "Quelle est l'importance de l'IRM dans le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM permet de visualiser les tumeurs et d'évaluer leur extension." } }, { "@type": "Question", "name": "Peut-on utiliser la cholangiographie pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la cholangiographie permet de visualiser les voies biliaires et détecter des obstructions." } }, { "@type": "Question", "name": "Quels symptômes peuvent alerter sur une tumeur ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs abdominales, jaunisse, et démangeaisons peuvent indiquer une tumeur." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des tumeurs biliaires ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur abdominale, jaunisse, et perte de poids." } }, { "@type": "Question", "name": "La jaunisse est-elle un symptôme fréquent ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la jaunisse est fréquente et résulte d'une obstruction des voies biliaires." } }, { "@type": "Question", "name": "Peut-on avoir des démangeaisons avec une tumeur biliaire ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les démangeaisons peuvent survenir en raison de l'accumulation de bile." } }, { "@type": "Question", "name": "Les nausées sont-elles un symptôme associé ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les nausées peuvent être présentes en raison de l'irritation du système digestif." } }, { "@type": "Question", "name": "Comment la douleur abdominale se manifeste-t-elle ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "La douleur est souvent localisée dans la partie supérieure droite de l'abdomen." } }, { "@type": "Question", "name": "Peut-on prévenir les tumeurs des voies biliaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais éviter l'hépatite et l'alcool peut aider." } }, { "@type": "Question", "name": "Quels facteurs de risque sont évitables ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'alcoolisme et l'exposition à des produits chimiques sont des facteurs évitables." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation saine peut réduire le risque de maladies hépatiques, mais pas spécifiquement." } }, { "@type": "Question", "name": "Les infections chroniques augmentent-elles le risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections chroniques comme l'hépatite B et C augmentent le risque." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est associé à un risque accru de plusieurs cancers, y compris biliaires." } }, { "@type": "Question", "name": "Quels sont les traitements possibles pour ces tumeurs ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie." } }, { "@type": "Question", "name": "La chirurgie est-elle toujours possible ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, la chirurgie dépend de la taille et de l'emplacement de la tumeur." } }, { "@type": "Question", "name": "Quand la chimiothérapie est-elle recommandée ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie est souvent utilisée pour les tumeurs avancées ou inopérables." } }, { "@type": "Question", "name": "La radiothérapie est-elle efficace ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La radiothérapie peut soulager les symptômes et est utilisée en complément." } }, { "@type": "Question", "name": "Y a-t-il des traitements ciblés disponibles ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements ciblés peuvent être utilisés selon le type de tumeur." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'obstruction biliaire, l'infection et la métastase." } }, { "@type": "Question", "name": "L'obstruction biliaire est-elle grave ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des douleurs sévères et des infections hépatiques." } }, { "@type": "Question", "name": "Les infections sont-elles fréquentes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections peuvent survenir en raison de l'obstruction des voies biliaires." } }, { "@type": "Question", "name": "Quelles sont les conséquences des métastases ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les métastases peuvent affecter d'autres organes et compliquer le traitement." } }, { "@type": "Question", "name": "Peut-on prévenir les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être évitées par un suivi médical régulier." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, l'hépatite chronique et l'exposition à des toxines." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de tumeurs biliaires ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente avec l'âge, surtout après 50 ans." } }, { "@type": "Question", "name": "Les maladies hépatiques augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies hépatiques chroniques comme la cirrhose augmentent le risque." } }, { "@type": "Question", "name": "L'exposition à l'arsenic est-elle un risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à l'arsenic est associée à un risque accru de cancers biliaires." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque." } } ] } ] }

Sources (10000 au total)

A Simplified Clinical Prediction Rule for Prognosticating Dependent Daily Living in Patients with Thoracic Spinal Cord Injury: A Multicenter Nationwide Japan Registry Study.

Clinical prediction rule (CPR) using decision tree analysis is able to show the branching of the variables under consideration in a clear, hierarchical manner, including specific reference values, whi... We extracted data on patients with thoracic SCI from a national multicenter registry database, the Japan Rehabilitation Database (JRD). All patients with thoracic SCI who were hospitalized within 30 d... Three hundred ten patients with thoracic SCI were included in the CART analysis. The CART model identified, in a hierarchical order, patient's age, residual function level, and the bathing sub-score o... We developed a simplified, moderately accurate CPR for predicting whether patients with thoracic SCI achieve independent living at hospital discharge....

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.

Iberdomide, a novel cereblon modulator (CELMoD... Forty subjects were enrolled in the study and divided into five groups based on hepatic function. 1 mg iberdomide was administered and plasma samples were collected to evaluate the pharmacokinetics of... After a single dose of iberdomide (1 mg), mean iberdomide Cmax (maximum observed concentration) and AUC (area under the concentration-time curve) exposure were generally comparable between hepatic imp... In summary, 1 mg single oral dose of iberdomide was generally well-tolerated. HI (mild, moderate or severe) had no clinically relevant impact on iberdomide PK and therefore, no dose adjustment is warr...

Intraoperative complication of radical cystectomy for muscle-invasive bladder cancer: does the surgical approach matter? A retrospective multicenter study using the EAUiaiC classification.

Despite surgical and anesthetic progress, radical cystectomy for bladder cancer remains one of the most morbid surgeries in urology. The objective of our study was to describe intraoperative complicat... We retrospectively reviewed medical records of patients treated by radical cystectomy for localized muscle invasive bladder cancer between 2015 and 2020, following the Martin et al. criteria for compl... A total of 318 patients were included for analysis. Among them, 17 patients (5.4%) presented an intraoperative complication. No preoperative oncological or clinical factor was associated with the occu... Radical cystectomy remains a highly morbid surgery and surgical approach did not improve the complication rate. Perioperative morbidity has a significant impact on patient survival. The association be...

Artificial intelligence-based computer-aided diagnosis system supports diagnosis of lymph node metastasis in esophageal squamous cell carcinoma: A multicenter study.

This study aimed to develop an artificial intelligence-based computer-aided diagnosis system (AI-CAD) emulating the diagnostic logic of radiologists for lymph node metastasis (LNM) in esophageal squam... A total of 689 ESCC patients with PET/CT images were enrolled from three hospitals and divided into a training cohort and two external validation cohorts. 452 CT images from three publicly available d... The AI-CAD achieved an accuracy of 0.744 for predicting pathological LNM in the external cohort and a good agreement with a human expert in two external validation cohorts (kappa = 0.674 and 0.587,... The AI-CAD could aid in preoperative diagnosis of LNM in ESCC patients and thereby support clinical treatment decision-making....

Estimation of the physiologic ability and surgical stress scoring system as a useful predictor of postoperative recurrence in patients with stage II colorectal cancer: a multicenter study.

We determined the usefulness of the estimation of physiologic ability and surgical stress (E-PASS), initially reported as a predictive factor for postoperative morbidity and mortality, as a prognostic... Overall, 739 patients who underwent proctocolectomy for CRC at Tottori University Hospital and affiliated hospitals and histologically diagnosed with stage II CRC were included in the current study.... A receiver operating characteristic (ROC) analysis of the five-year recurrence-free survival indicated that the comprehensive risk score (CRS) of E-PASS predicted postoperative recurrence. A multivari... The CRS predicts postoperative recurrence in patients with stage II CRC....

The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.

The 31-gene expression profile test (Class 1A: low-risk; 1B/2A: intermediate-risk; 2B: high-risk) is validated to identify patients with cutaneous melanoma who can safely forego sentinel lymph node bi... Patients with T1-T2 tumors eligible for SLNB were seen by surgical oncologists (89.1%), dermatologists (7.8%), and medical oncologists (3.1%). After receiving 31-GEP results but before SLNB, clinician... One hundred clinical decisions (52.4%) were influenced by the 31-GEP to forego SLNB and 70% (70/100) were not performed. Of the 30 performed, 0% (0/30) were positive. The 31-GEP influenced sixty-three... In this prospective, multicenter study, clinicians demonstrated clinically meaningful use of the 31-GEP test to forego or pursue SLNB in patients with T1-T2 tumors resulting in a significant, risk app...

A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E.

High grade, non-muscle invasive bladder cancer (NMIBC) is usually treated with intravesical Bacillus Calmette-Guérin. Chemohyperthermia therapy (CHT) may be a novel alternative therapy for the treatme... To evaluate the recurrence-free survival (RFS) of patients treated with CHT using the Combat bladder recirculation system (BRS) for NMIBC.... This was a prospective multi-institutional study of 1,028 consecutive patients with NMIBC undergoing CHT between 2012 and 2020. A total of 835 patients were treated with CHT with Mitomycin C (MMC). Di... Median follow up was 22.4 months (Interquartile range (IQR): 12.8 -35.8). Median age was 70.4 years (IQR: 62.1 -78.6). A total of 557 (66.7%), 172 (20.6) and 74 (8.9%) of patients were classified to B... CHT with MMC using the Combat BRS is effective in the medium term and has a favorable adverse event profile....

Assessment of predictors of early postoperative complications after primary robotically assisted Roux-en-Y gastric bypass: a multicenter, retrospective cohort study.

Robotic Roux-en-Y gastric bypass (RRYGB) is performed in an increasing number of bariatric centers worldwide. Previous studies have identified a number of demographic and clinical variables as predict... A retrospective analysis of two prospective databases containing patients who underwent RRYGB between 2006 and 2019 at two high volumes, accredited bariatric centers was performed. Primary outcome was... Data of 1276 patients were analyzed, including 958 female and 318 male patients. Rates of overall and severe 30 day complications were 12.5% (160/1276) and 3.9% (50/1276), respectively. Rate of 30 day... This study identified male sex and ASA score >2 as independent predictors of early postoperative complications after RRYGB. These data suggest a potentially different risk profile in terms of early po...

Prescription Opioid Use among Patients with Chronic Noncancer Pain before and after the COVID-19 Outbreak in Taiwan: A Multicenter Prospective Observational Study.

The COVID-19 outbreak disrupted medical access for patients receiving chronic opioid therapy. This study investigated their prescription opioid dosages before and after the 2020 outbreak in Taiwan.... A prospective questionnaire survey was conducted among registered outpatients receiving long-term opioids before July 2019 in Taiwan. The questionnaire included items from the Taiwanese Brief Pain Inv... After a mean of 531 days, the questionnaire responses of 103 of the initial 117 respondents were reviewed. Daily opioid doses decreased for 31 respondents (30.1%), remained roughly equivalent (defined... The COVID-19 outbreak in 2020 did not interrupt access to long-term opioid prescriptions for most registered patients with chronic pain in Taiwan. Less fentanyl patch use was observed in participants ...

Efficacy of extended focused assessment with sonography for trauma using a portable handheld device for detecting hemothorax in a low resource setting; a multicenter longitudinal study.

Chest trauma is one of the most important and commonest injuries that require timely diagnosis, accounting for 25-50% of trauma related deaths globally. Although CT scan is the gold standard for detec... This was an observational longitudinal study that enrolled 104 study participants with chest trauma. Informed consent was obtained from all participants. A questionnaire was administered and eFAST, ch... eFAST was found to be superior to chest X-ray with sensitivity of 96.1% versus 45.1% respectively. The accuracy was also higher for eFAST (96.4% versus 49.1%) but the specificity was the same at 100.0... This study revealed that eFAST was more sensitive at detecting haemothorax among chest trauma patients compared to chest X-ray. All patients presenting with chest trauma should have bedside eFAST for ...